DCM
GILD icon

DGS Capital Management’s Gilead Sciences GILD Stock Holding History

DGS Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$36.8K – 661
2025
Q4 		$36.8K Buy
+300
New +$36.5K 0.01% 529

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

DGS Capital Management's GILD Position: Q1 2026 in Review

DGS Capital Management increased its Gilead Sciences (GILD) stake by 9.8% in Q1 2026, buying an estimated $175K and bringing the position to 14,029 shares worth $1.96M. The position accounts for 0.32% of the portfolio, ranked #58.

DGS Capital Management first reported a position in GILD in Q2 2022 and has held it in 16 quarters since. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • DGS Capital Management held 14,029 shares of Gilead Sciences worth $1.96M as of Q1 2026.
  • DGS Capital Management bought 1,253 Gilead Sciences shares in Q1 2026, an estimated $175K.
  • Gilead Sciences made up 0.32% of DGS Capital Management's portfolio in Q1 2026, its #58 holding.
  • DGS Capital Management first reported a position in Gilead Sciences in Q2 2022 and has held it in 16 quarters since.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.